Takeda invests 300 million euros in Belgian plasma-derived therapies production

Coinciding with the 50th anniversary of its Lessines, Belgium, site, Japanese pharma major Takeda (TYO: 4502) said it is investing close to 300 million euros ($304 million) in a new state-of-the-art production facility for the manufacturing of plasma-derived therapies for people with rare and complex chronic diseases.

This is the biggest investment to date for Takeda in Belgium, and the announcement was made at a celebration this week attended by local dignitaries, included the deputy prime minister and Japan’s ambassador to Belgium.

Plasma-derived therapies are used to treat patients with complex diseases, such as primary or acquired immunodeficiencies, or rare diseases like hereditary angioedema and bleeding disorders. People with these conditions may require lifesaving treatment for acute emergencies, as well as lifelong substitution therapy.